MARKET

SYRE

SYRE

Spyre Therapeutics
NASDAQ
29.90
+2.46
+8.97%
After Hours: 29.90 0 0.00% 16:00 03/01 EST
OPEN
30.18
PREV CLOSE
27.44
HIGH
32.99
LOW
28.48
VOLUME
1.00M
TURNOVER
0
52 WEEK HIGH
32.99
52 WEEK LOW
2.660
MARKET CAP
1.08B
P/E (TTM)
-0.3937
1D
5D
1M
3M
1Y
5Y
Wells Fargo Upgrades Spyre Therapeutics to Overweight, Raises Price Target to $35
Benzinga · 15h ago
Spyre Therapeutics: [Amend]Annual Report
Press release · 17h ago
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX), Madrigal Pharmaceuticals (MDGL) and Spyre Therapeutics (SYRE)
TipRanks · 18h ago
Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)
TipRanks · 19h ago
Buy Rating for Spyre Therapeutics: Anticipated Clinical Trials and Strategic Advantages Propel Optimism
BTIG analyst Julian Harrison maintained a Buy rating on Spyre Therapeutics. The anticipated first-in-human trials for their leading drug candidates, SPY001 and SPY002, are set to commence in the first and second halves of 2024. The company’s price has risen 4981.48% in the past six months.
TipRanks · 20h ago
TD Cowen Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
TipRanks · 1d ago
Spyre Therapeutics GAAP EPS of -$4.05
Spyre Therapeutics, Inc. Has $340 million of cash, cash equivalents, and restricted cash as of December 31, 2023. The company posted a Q4 GAAP EPS of -$4.05. Spyre has a runway into the second half of 2026.
Seeking Alpha · 1d ago
Spyre Therapeutics Q4 EPS $(4.05) Up From $(5.00) YoY
Benzinga · 1d ago
More
About SYRE
Spyre Therapeutics, Inc., formerly Aeglea BioTherapeutics, Inc., is a biotechnology company. The Company focuses to create the next generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Its pipeline includes extended half-life antibodies targeting α4β7, tumor necrosis factor-like ligand 1A (TL1A), and IL-23. Its pipeline programs include SPY001, SPY002, SPY003, SPY004, SPY120, SPY130, and SPY230. Its advanced product candidate, SPY001, is designed to be a highly potent, selective, and fully humanized monoclonal immunoglobulin G1 antibody that binds selectively to the α4β7 integrin. Its co-lead product candidate, SPY002 is designed to be a highly potent, highly selective, and fully humanized monoclonal antibody that binds to TL1A. SPY003 is a highly potent and selective monoclonal antibody product candidate targeting the p19 subunit of IL-23.

Webull offers Spyre Therapeutics Inc stock information, including NASDAQ: SYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRE stock methods without spending real money on the virtual paper trading platform.